Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

Circulating Soluble Urokinase-Type Plasminogen Activator Receptor Levels Reflect Renal Function in Newly Diagnosed Patients with Multiple Myeloma Treated with Bortezomib-Based Induction

(1) Background: Soluble urokinase-type plasminogen activator receptor (suPAR) has been implicated in the pathogenesis of kidney disease in different disease settings. The aim of this study was to investigate a possible link between suPAR circulating levels and renal impairment (RI) in newly diagnose...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Ioannis Ntanasis-Stathopoulos, Gerasimos-Petros Papassotiriou, Efstathios Kastritis, Alexandra Margeli, Nikolaos Kanellias, Evangelos Eleutherakis-Papaiakovou, Magdalini Migkou, Despina Fotiou, Maria Roussou, Maria Gavriatopoulou, Panagiotis Malandrakis, Erasmia Psimenou, Ioannis Papassotiriou, Meletios A. Dimopoulos
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:Journal of Clinical Medicine
Subjects:
suPAR
soluble urokinase-type plasminogen activator receptor
multiple myeloma
bortezomib
induction
kidney
Online Access:https://www.mdpi.com/2077-0383/9/10/3201

Similar Items

Similar Items